Tag Archives: DE

EU fines Volkswagen, BMW $1 bln for emissions cartel

  • Sets precedent by applying antitrust law to technical talks
  • Daimler gets off fine after blowing whistle on cartel
  • VW considering taking legal action
  • BMW says cleared of suspicion of emissions cheating

BRUSSELS, July 8 (Reuters) – The European Commission fined German carmakers Volkswagen and BMW a total of 875 million euros ($1 billion) on Thursday for colluding to curb the use of emissions cleaning technology they had developed.

The case, separate to the so-called ‘Dieselgate’ scandal over software designed to cheat on vehicle emissions tests, sets a precedent by extending the application of European competition law to technical-level talks between industry players.

In this case, talks held a decade ago centred on design standards for AdBlue, an additive used to cleanse nitrogen oxide from the exhaust gases produced by diesel-powered cars.

“This is a first,” European Union antitrust chief Margrethe Vestager told a news conference in Brussels. “We have never had a cartel whose purpose was to restrict the use of novel technology.”

Under a settlement, Volkswagen (VOWG_p.DE) will pay a fine of 502 million euros and BMW (BMWG.DE) 373 million euros. Daimler, also part of the cartel, was not fined after revealing its existence.

Vestager said the German carmakers, which included VW units Audi (AUDVF.PK) and Porsche (PSHG_p.DE), had possessed the technology to reduce harmful emissions more than required under EU law but avoided competing to do so.

“So today’s decision is about how legitimate technical cooperation went wrong. And we do not tolerate it when companies collude,” said Vestager.

The EU had narrowed the original scope of its investigation to ensure its charges stuck.

IS TECHNICAL COLLUSION POSSIBLE?

Vestager said that all of the parties had agreed to settle the case and “have acknowledged their role in this cartel”.

Volkswagen, however, said it was considering whether to take legal action, saying the penalty over technical talks about emissions technology set a questionable precedent. read more

“The Commission is entering new judicial territory, because it is treating technical cooperation for the first time as an antitrust violation,” Volkswagen said, adding that the fines had been set even though no customers had suffered any harm.

The nub of the carmakers’ complaints boil down to whether setting common technical standards amounts to anti-competitive behaviour – or whether indeed it makes it easier for an industry as a whole to embrace new technology.

The Commission said in its 2019 charge sheet that the German carmakers had colluded to restrict the size of AdBlue tanks between 2006 and 2014, thus making the urea-based additive less convenient to use.

BMW noted in its defence that it had been cleared of suspicion of using illegal ‘defeat devices’ to cheat emissions tests. read more

“This underlines that there has never been any allegation of unlawful manipulation of emission control systems by the BMW Group,” BMW said in a statement.

In the Dieselgate scandal, VW admitted to using such defeat devices, leading to more than 32 billion euros ($38 billion) in vehicle refits, fines and legal costs for the Wolfsburg-based carmaker.

($1 = 0.8460 euros)

Editing by John Chalmers, Douglas Busvine, Maria Sheahan, Elaine Hardcastle

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

South Korea considers reimposing restrictions as COVID-19 cases surge

  • S.Korea reports 1,212 new daily cases
  • Movement restrictions extended in Seoul
  • Officials warn tougher curbs could be reinstated
  • Delta variant being fuelled by young and unvaccinated

SEOUL, July 7 (Reuters) – South Korea reported its second highest number of daily new COVID-19 cases ever on Wednesday, just days after it began easing social distancing restrictions in some parts of the country, buoyed by an accelerated vaccine rollout.

With the majority of the 1,212 new cases coming from densely populated Seoul, officials extended movement curbs in the capital and surrounding regions for at least another week and are considering pushing restrictions back up to the highest level.

Prime Minister Kim Boo-kyum said the country’s fourth wave of the virus, fuelled by the highly contagious Delta variant, was spreading rapidly, especially among unvaccinated people in their 20s and 30s.

Kim urged people in that demographic to get tested preemptively “to protect not just yourself, but everyone in your family, friends, school and the country.”

“If the situation is not under control after monitoring for two to three days, it might leave us with no choice but to impose the strictest of all social distancing levels,” Kim said.

President Moon Jae-in ordered the military be mobilized to aid wider contact tracing and urged authorities to install additional testing centres in densely populated areas, presidential spokeswoman Park Kyung-mee told reporters on Wednesday.

The daily caseload was the worst since Dec. 25, when South Korea was experiencing a third wave of the pandemic.

Officials had been moving in recent weeks toward a full reopening of the country. Movement restrictions in much of the country were eased on July 1, although officials in greater Seoul held off as they watched case numbers beginning to creep up again. read more

Health experts said the relaxation of measures that restricted business operating hours and social gatherings outside of Seoul, along with the knowledge that further easings would be coming, led to public complacency, particularly in socially mobile younger people in the capital.

Around 85% of the new locally transmitted cases were in the Seoul metropolitan area, which is home to more than half of the country’s population.

“While the infection rate has dropped relatively in the people aged over 60 on the back of inoculation drive, the transmission continues in the unvaccinated group,” said Kim Tark, associate professor of infectious disease at Soonchunhyang University Bucheon Hospital.

“It’s a reminder to speed up vaccination for people under 60.”

VACCINES ARRIVE

Just 10% of the country’s population of 52 million people have been fully vaccinated, while 30% have received at least one shot, the majority of them aged over 60.

The Korean Medical Association urged the government to refrain from any hasty decisions to ease social distancing policies with vaccinations at low levels.

The country received 700,000 doses of the Pfizer/BioNTech vaccine (PFE.N), (22UAy.DE) from Israel on Wednesday under a swap arrangement, along with a separate shipment of 627,000 directly purchased doses. read more

Some of the new supply will be sent to greater Seoul for inoculation programmes due to start on July 13, authorities said.

Improved vaccination levels have helped lower South Korea’s mortality rate to 1.25% and the number of severe cases to 155 as of Wednesday, down significantly from 1.41% and 311 cases reported during the previous peak in late December.

The country has reported a total of 162,753 infections and 2,033 deaths during the pandemic.

Reporting by Sangmi Cha; Editing by Miyoung Kim and Jane Wardell

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Iran begins process of making enriched uranium metal; U.S., E3 dismayed

VIENNA/WASHINGTON, July 6 (Reuters) – Iran has begun the process ofproducing enriched uranium metal, the U.N. atomic watchdog said on Tuesday, a move that could help it develop a nuclear weapon and that three European powers said threatened talks to revive the 2015 Iran nuclear deal.

Iran’s steps, which were disclosed by the International Atomic Energy Agency and which Tehran said were aimed at developing fuel for a research reactor, also drew criticism from the United States, which called them an “unfortunate step backwards.”

U.S. and European officials made clear that Iran’s decision would complicate, and potentially torpedo, indirect U.S.-Iranian talks seeking to bring both nations back into compliance with the 2015 deal, which was abandoned by former U.S. President Donald Trump.

The deal imposed curbs on Iran’s nuclear programme to make it harder for Tehran to develop fissile material for nuclear weapons in return for the lifting of economic sanctions. After Trump withdrew, Iran began violating many of its restrictions.

Tehran has already produced a small amount of uranium metal this year that was not enriched. That is a breach of the deal, which bans all work on uranium metal since it can be used to make the core of a nuclear bomb. read more

“Today, Iran informed the Agency that UO2 (uranium oxide) enriched up to 20% U–235 would be shipped to the R&D laboratory at the Fuel Fabrication Plant in Esfahan, where it would be converted to UF4 (uranium tetrafluoride) and then to uranium metal enriched to 20% U–235, before using it to manufacture the fuel,” an IAEA statement said.

A confidential IAEA report seen by Reuters said the agency had confirmed that Iran had taken the second of the four steps described, making clear it has begun the process.

Britain, France and Germany said on Tuesday they had “grave concern” about Iran’s decision, which violates the nuclear deal formally named the Joint Comprehensive Plan of Action (JCPOA). read more

“Iran has no credible civilian need for uranium metal R&D and production, which are a key step in the development of a nuclear weapon,” they said in a joint statement issued by Britain’s foreign ministry.

“With its latest steps, Iran is threatening a successful outcome to the Vienna talks despite the progress achieved in six rounds of negotiations,” they said, and urged Iran to return to the talks, which began in April and adjourned on June 20. No date has been set for a next round.

U.S. State Department spokesman Ned Price said that Washington was not setting a deadline for the talks but noted “that as time proceeds Iran’s nuclear advances will have a bearing on our view of returning to the JCPOA.”

Price said the United States found it “worrying” that Iran was continuing to violate the agreement “especially with experiments that have value for nuclear weapons research.

“It’s another unfortunate step backwards for Iran,” he said.

Reporting by Francois Murphy in Vienna and by Humeyra Pamuk and Arshad Mohammed in Washington;
Additional reporting by Doina Chiacu, Jonathan Landay and Simon Lewis in Washington and by David Milliken in London;
Writing by Francois Murphy and Arshad Mohammed
Editing by David Goodman and Sonya Hepinstall

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Germany could ease travel curbs as Delta variant takes over

People walk past a colonnade on Museum Island during warm temperatures, amid the coronavirus disease (COVID-19) pandemic, in Berlin, Germany May 30, 2021. REUTERS/Annegret Hilse

BERLIN, July 1 (Reuters) – Germany expects the Delta variant of COVID-19 to account for up to 80% of infections this month and could ease travel restrictions from countries like Portugal and Britain where it already dominates, its health minister said on Thursday.

Jens Spahn told a news conference that Germany could reduce the current 14-day quarantine requirement that it imposes on travellers from countries with high levels of the Delta variant once it is sure that vaccinated people are protected.

Spahn said the move could happen soon, without specifying.

Germany’s STIKO vaccination commission said later on Thursday that UK studies show that two vaccines doses seem to provide as much protection against the Delta variant as against other COVID-19 variants. read more

Spahn reiterated the importance of speeding up vaccinations, noting that 37% of Germany’s population has now received two shots, while 55% has had a first dose.

About half of German coronavirus cases are currently Delta variant and Spahn said it will dominate later this month.

Germany last week declared Portugal and Russia to be “virus-variant zones”, meaning only German residents can enter the country from those countries and still face a mandatory two-week quarantine even if they are fully vaccinated or test negative.

That had prompted German tourists there to rush home and airlines to cancel flights.

Germany also classifies Britain as such a “virus variant” zone. Chancellor Angela Merkel is due to discuss travel restrictions when she meets British Prime Minister Boris Johnson on Friday.

Spahn suggested these countries could be shifted to a designation as risk areas, meaning people can travel if they are fully vaccinated or have recovered from COVID-19, or be released from quarantine after five days if they test negative.

The European Commission said on Tuesday that Germany should not impose a travel ban on Portugal but limit itself to imposing testing and quarantine requirements to be in line with the European Union approach meant to ease summer travel.

Reporting by Emma Thomasson and Thomas Escritt; Editing by Maria Sheahan and Catherine Evans

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

CureVac COVID-19 vaccine records only 48% efficacy in final trial readout

A dose of CureVac vaccine or a placebo is seen during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves Herman

June 30 (Reuters) – CureVac (5CV.DE) said its COVID-19 vaccine was 48% effective in the final analysis of its pivotal mass trial, only marginally better than the 47% reported after an initial read-out two weeks ago.

The German biotech firm said that efficacy, measured by preventing symptomatic disease, was slightly better at 53% when excluding trial participants older than 60 years, an age group that is by far the most severely affected.

CureVac said on June 16 its COVID-19 vaccine, known as CVnCoV, proved only 47% effective in an initial trial read-out and that new variants had proved a headwind, denting investor confidence in its ability to take on rival shots.

That wiped billions of euros from its market value.

Wednesday’s news sent U.S.-listed shares of the company 10.2% lower to $66 after the bell.

Late-stage trials of BioNTech/Pfizer (22UAy.DE), (PFE.N) and Moderna (MRNA.O) vaccines, which like CureVac’s are based on mRNA technology, had efficacy rates of well above 90% across all age groups but took place when the original version of the coronavirus was dominant.

Data on their products have, however, so far suggested only somewhat weaker protection against new variants.

The CureVac study, which involved about 40,000 adult volunteers in Europe and Latin America, showed that efficacy was 77% in the age group below 60 years of age when considering only moderate to severe symptoms and excluding mild cases.

CureVac said it had sent the data to the European Medicines Agency (EMA) as part of an ongoing dialogue with the EU drugs regulator.

CureVac previously said that the regulatory hurdle was 50% efficacy in principle but that various other considerations would come into play.

“In this final analysis, CVnCoV demonstrates a strong public health value in fully protecting study participants in the age group of 18 to 60 against hospitalization and death and 77% against moderate and severe disease – an efficacy profile, which we believe will be an important contribution to help manage the COVID-19 pandemic and the dynamic variant spread,” said Chief Executive Officer Franz-Werner Haas.

CureVac had registered 228 infections overall for the final analysis, after 134 cases for the interim analysis.

Public health representatives across the globe are pushing for a fast deployment of available vaccines to counter highly contagious mutations of COVID-19 such as the Delta variant that first emerged in India.

The EMA has said it would not impose a 50% efficacy threshold for vaccines and that full trial data was necessary for it to make a sound assessment on the benefits and risks of a shot. read more

Under CureVac’s only major supply deal for the product tested in the trial, the European Union secured up to 405 million doses of the vaccine in November, of which 180 million are optional.

In a bet on CureVac’s technology, Britain placed a conditional 50 million dose order in February on yet-to-be-developed vaccines that build on the product tested in the trial. read more

CureVac had lined up a network of manufacturing partners including Celonic Group of Switzerland, Novartis (NOVN.S), Bayer (BAYGn.DE), Fareva, Wacker (WCHG.DE) and Rentschler Biopharma SE.

($1 = 0.8377 euros)

Reporting by Ludwig Burger, Editing by Rosalba O’Brien

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Cathie Wood Extends Hot Streak With ARK Space Exploration ETF

Cathie Wood’s

new

ARK Space Exploration & Innovation ETF

ARKX -1.09%

is already on track to be one of the most successful fund launches ever despite criticism that it doesn’t necessarily reflect the nascent space-exploration market.

Investors poured $536.2 million into the actively managed exchange-traded fund, known as ARKX, in its first five days of trading, according to FactSet data through Tuesday. That trounces the industry average of three years to gather $100 million and puts the fund on course to top $1 billion in assets within days, analysts said.

Such a milestone would put the fund in rare company: The fastest ETF to reach $1 billion was

State Street’s

SPDR Gold Trust

GLD -0.01%

fund, which hit the mark in just three days back in 2004.

“That speaks to the overall power of ARK right now,” said Nate Geraci, president of ETF Store, an investment-advisory firm. “At this point, investors think anything Cathie Wood touches turns to gold.”

The fund is ARK Investment Management LLC’s first launch in two years and stands in contrast to the lukewarm receptions its earlier products received. ARK’s flagship innovation fund, begun in 2014, took more than 3 1/2 years to reach $1 billion. Its last launch, the fintech innovation ETF in 2019, took about 21 months.

A lot has changed for ARK, though. In the span of a year, Ms. Wood’s ARK has transformed from a small, upstart manager of a handful of ETFs to one of the biggest fund managers in the U.S. The share prices of the firm’s five other actively managed ETFs doubled or tripled last year on the back of surging growth stocks such as

Tesla Inc.

and Roku Inc., earning Ms. Wood a cultlike following of individual investors who hang on her every tweet and video.

But those growth stocks are now the epicenter of a selloff that has left ARK’s older funds down at least 14% from their highs earlier this year. Rather than rolling out another fund primary tied to the tech trade, ARK has tilted nearly half of its space ETF toward manufacturers including

Lockheed Martin Corp.

,

Boeing Co.

and

Deere

DE 0.03%

& Co., a sector of the stock market that has benefited in recent months from rising interest rates and inflation expectations.

The fund is different enough for investors who say they are fans of Ms. Wood but also wary of plowing more money into a faltering tech trade.

“Most of Cathie’s ETFs are tech-heavy,” said Tré Diemer, 20 years old, a student at William & Mary who said he bought a couple of thousand dollars of ARKX shares Monday. “You look at this ETF and see a lot of names she hasn’t been as involved with.”

He already owns a variety of growth stocks and has been eyeing Ms. Wood’s other funds as a home for some of the money he earns from working as an emergency medical technician and running deliveries for

DoorDash Inc.

But tech and Ms. Wood’s other funds seemed overvalued, a point reinforced by the recent losses he said he sustained.

“You can look at this almost as a reopening ETF,” said Mr. Diemer, referring to underlying stocks poised to benefit most from a rebounding economy.

Not everyone is a fan of the fund’s makeup. Some took to social media, creating memes to mock ARK’s decision to include Deere and other companies that appear to have no significant ties to the fund’s theme of investing in space exploration and innovation. One showed a Deere tractor roving across a Mars landscape, another on the moon.

Deere, for its part, responded with several of its own memes, including one showing a UFO beaming up a tractor. Some analysts said the inclusion of Deere is less of a stretch when considering that the company makes satellite-guided machinery.

Other stocks included in the fund that seem at odds with its mandate include ARK’s passively managed 3D-printing ETF and shares of

Netflix Inc.

and

Amazon.com Inc.

Meanwhile, some of the few pure-play space stocks such as the satellite and imaging company

Maxar Technologies Inc.

didn’t make the cut. Neither did Rocket Lab USA Inc. nor Astra Space Inc., two rocket makers that are merging with blank-check companies to go public.

Ren Leggi,

a client portfolio manager at ARK, acknowledged that the holdings are causing some confusion but said that they are all in line with the fund’s mandate. “When we’re talking about space exploration and innovation, we define it as everything above ground,” said Mr. Leggi.

Share Your Thoughts

What explains the success of Cathie Wood’s latest exchange-traded fund? Join the conversation below.

The advancement of drone technology plays a big part in why several companies, including Amazon, are in the fund, said Mr. Leggi. Netflix would benefit from the rollout of satellites that enable further adoption of broadband internet for streaming, and some rocket parts are 3D-printed, he added. As for the space companies left out, Mr. Leggi said valuations of some were too rich, especially those involved with special-purpose acquisition companies, while others didn’t pass their initial evaluation of whether the stock could sustain a 15% annualized return rate.

“We still continue to track a lot of companies in case we get a market environment where there’s a broader selloff and we can get in at an attractive price,” Mr. Leggi said.

Some investors remain unconvinced.

“I was not too fond of its holdings,” said Carter Wang, who is 19 and has roughly $3,000 in four of ARK’s earlier funds. He is a fan of Ms. Wood, citing her aggressive calls on Tesla as a key reason behind his decision to invest in several of the firm’s funds. But Mr. Wang, a business management economics major at the University of California, Santa Cruz, called the inclusion of ARK’s 3D-printing ETF odd, leading him to pass on the fund.

For several ARK investors, Ms. Wood’s past performance is key. With shares of ARKX trading around $21, some investors said they see a chance to get into the firm’s next success, likening it to ARK’s innovation fund, whose share price is six times higher since it launched in 2014 and continues to command investors’ attention. (The ETF saw record daily inflows one day last week, pulling in more than $700 million.)

“It doesn’t really bother me,” said James Carter, a 31-year-old tech writer in Washington, D.C., who snapped up shares on the space fund’s first day of trading. He said his mind was set on investing in the fund since he first heard about it earlier this year, even before any of its underlying stocks had been announced. He is holding out for the possibility that the fund ends up including shares of Elon Musk’s privately held rocket company, Space Exploration Technologies Corp.

“I was kind of late” with the other funds, Mr. Carter said of his other ARK investments. “So I specifically set money aside for the new ARK fund just because of my interest in ARK. I wanted to get in early.”

What You Need to Know About Investing

Write to Michael Wursthorn at Michael.Wursthorn@wsj.com

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Read original article here